Drugs / DV281
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03326752 | Sep 2017 → Sep 2019 | non-small cell lung carcinoma | Dynavax Technologies Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DV281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03326752 ↗ |
| Route | Inhaled | “inhaled DV281” NCT03326752 ↗ |